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We describe the first reported cases of invasive type e Hae-
mophilus influenzae disease in Italy. All five cases occurred in
adults. The isolates were susceptible to ampicillin and eight
other antimicrobial agents. Molecular analysis showed two dis-
tinct type e strains circulating in Italy, both containing a single
copy of the capsulation locus. 
n Italy, the vaccine against Haemophilus influenzae type b
(Hib) was licensed in 1995, but vaccination is voluntary.
Vaccination coverage by 24 months of age was estimated in
1998 at 19.8 % for the 1996 birth cohort (1). Coverage
increased in 2000 to 53.1% for the 1998 birth cohort (2). Since
1994, surveillance of H. influenzae meningitis has been con-
ducted within the National Surveillance of Bacterial Meningi-
tis (3). A laboratory-based active surveillance of invasive H.
influenzae disease was implemented in a sample of Italian
regions in 1997 (4). In 1997–1998, the incidence of invasive
Hib disease estimated by this system was lower than that
reported in northern and central Europe and in the United
States before mass vaccination was introduced, yet was com-
parable with the incidence reported in other Mediterranean
countries with similar vaccination coverage (4).
In 1998–2001, laboratory-based active surveillance was
conducted in seven Italian regions, including a population of
approximately 24 million persons (33% of the Italian popula-
tion). Participating regions were located throughout the coun-
try and included rural, urban, and large metropolitan areas.
Active H. influenzae case finding was conducted by contact-
ing, monthly, microbiologists from the regional laboratories
of hospitals with infectious disease or pediatric wards. A
patient with invasive disease was defined as a patient with a
compatible illness, accompanied by isolation of H. influenzae
from a normally sterile site or detection of Hib antigen in
cerebrospinal fluid. Hospital microbiologists were asked to
send H. influenzae isolates to the national reference labora-
tory at Istituto Superiore di Sanità, where all strains were
assayed by polymerase chain reaction (PCR) capsular geno-
typing. Serotyping by slide agglutination was performed at
the regional level, when possible, and at the national refer-
ence laboratory. 
From 1998 to 2001, a total of 219 cases of invasive H.
influenzae disease were reported; 165 were diagnosed by iso-
lation of H. influenzae from a normally sterile site, and 54
were diagnosed by detection of Hib antigen in cerebrospinal
fluid. Of the 165 isolates, 97 (58.8%) were sent to the national
reference laboratory; the percentage of isolates sent to the ref-
erence laboratory remained relatively stable over the years
(from 62.3% in 1998 to 58.3% in 2001). Analysis of incidence
data by serotype showed that the annual number of cases of
invasive Hib disease decreased from 69 in 1998 to 17 in 2001,
while the number of nontypable H. influenzae remained con-
stant (mean 8 cases/year; range 7–11) (Table 1). No cases
attributable to capsulated H. influenzae other than type b were
detected in years 1998–1999; in the next 2 years, a total of
seven cases were traced; five were due to type e strain. 
We describe these five cases of invasive disease caused by
H. influenzae type e (Hie). Genetic relationship among the five
Hie isolates was assessed by pulsed-field gel electrophoresis
(PFGE). Susceptibility to nine antimicrobial agents, including
ampicillin, was also determined. Because amplification of cap-
sulation (cap) locus is assumed to contribute to strain viru-
lence, the copy number of cap e locus in each isolate was also
identified.
The Study
Five Hie isolates were detected through surveillance from
January 2000 to December 2001. Characteristics of patients
were obtained by reviewing clinical records (Table 2). Briefly,
two cases, both with meningitis, occurred in young adults,
who recovered. The remaining three cases, two with bactere-
mic pneumonia and one with septicemia, were in elderly
patients, who died. All but one (no. 2) of the patients were
from neighboring regions in northeastern Italy. However, the
towns they lived in were quite distant, and the patients were
admitted to different hospitals in different periods. Serotyping
of the isolates by slide agglutination was performed by using
polyvalent and monovalent antisera to capsular serotypes a
through f (Difco Laboratories, Detroit, MI). Capsular genotype
was identified by PCR (5). Briefly, in a first round of PCR,
primers to the ompP2 gene were used to confirm the H. influ-
enzae species, while primers directed to the bex region con-
firmed capsulation. A second round of PCR with primers
directed to the cap e–specific region (6) generated an expected
product of 1,350 bp. Further characterization of the isolates
was performed by phenotypic and genotypic methods. Bio-
types were assigned by determining indole production, urease
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level, and ornithine decarboxylase activities. MICs of ampicil-
lin were determined by E-test (AB Biodisk, Solna, Sweden).
Hib strain ATCC 10211 was used as control. Susceptibilities to
trimethoprim/sulfamethoxazole, ceftazidime, chlorampheni-
col, azithromycin, aztreonam, ciprofloxacin,  imipenem, and
tetracycline were tested by disk diffusion assay. Both the E-
test and the disk diffusion assay were performed by using Hae-
mophilus test medium, as recommended by the National Com-
mittee for Clinical Laboratory Standards (NCCLS) (7).
Interpretative breakpoints and zone diameters were also based
on NCCLS criteria. Production of β -lactamase was detected by
the cefinase disk test (BBL, Becton-Dickinson, Sparks, MD).
Restriction fragment length polymorphism analysis by PFGE
was conducted as described (5), except for digestion of
genomic DNA, performed by using SmaI (20 U) or ApaI
(20 U) restriction enzymes (New England BioLabs, Wilbury
Way Hitchin, U.K.). The copy number of cap e locus was
determined by Southern blot analysis, using as probe the
1,350-bp amplicon obtained by PCR of a prototype type e
strain. Since the KpnI and SmaI sites flank the cap locus of
encapsulated  H. influenzae strains, the copy number of the
locus can be estimated by the size of the restriction fragment
obtained after digestion of the chromosome with these
enzymes (8). Restriction fragments were separated by PFGE
as described (5), transferred to nylon membranes, and hybrid-
ized with the probe. Labeling of the probe and hybridization
reactions were obtained by using the ECL kit (Amersham
Pharmacia Biotech, Little Chalfont, U.K.). Hybridizing bands
were visualized by autoradiographs. Although no data are
available on the size of cap e locus, on the basis of results
obtained on Hib strains, the DNA fragment for a single-copy
strain was expected to be approximately 27–28 kb. In fact, the
KpnI/SmaI fragment includes the cap locus, whose size is 18
kb in Hib strains, plus additional segments (about 10 kb)
upstream and downstream of the cap region (8). Strains with
two or more copies of the cap b locus featured fragments of
increased size (45 kb, 63 kb, 81 kb, 99 kb) (8). 
By PCR, all isolates exhibited the type e capsular geno-
type. By slide agglutination method, performed at the national
reference laboratory, four isolates were designed as type e, and
one was misidentified as nontypable. At the regional level,
only one of the five PCR-positive strains had been recognized
as type e, two had been identified as nontypable, and two had
not been typed. By biotyping, four isolates were classified as
biotype IV, and one as biotype I (patient no. 5) (Table 2). MICs
of ampicillin ranged from 0.125 µg/mL to 0.25 µg/mL, indi-
cating that all isolates were susceptible to this antibiotic; none
produced β -lactamase. As assessed by disk diffusion assay, all
isolates were also susceptible to trimethoprim/sulfamethox-
azole, ceftazidime, chloramphenicol, azithromycin, aztre-
onam, ciprofloxacin, imipenem, and tetracycline. PFGE with
SmaI restriction enzyme digestion generated not well-resolved
profiles, as several very close fragments of 194–145 kb were
obtained (data not shown). Following ApaI digestion, profiles
were easier to compare (Figure): three isolates (patients no. 3,
4, and 5) shared an indistinguishable pattern (pattern 1); one
isolate (patient no. 1) showed a profile closely related to pat-
tern 1 but with two band differences (pattern 1a). The isolate
from patient no. 2 appeared clearly different from the others
(pattern 2), according to criteria reported by Tenover et al. (10)
Table 1. Incidence per 100,000 persons and cases of invasive Haemophilus influenzae disease, by serotype, Italy, 1998–2001 
Incidence per 100,000 (no. of cases)
H.  influenzae 1998 1999 2000 2001
All capsular types plus nontypablea 0.35 (84) 0.26 (64) 0.16 (40) 0.13 (31)
Type b 0.28 (69) 0.18 (44) 0.09 (21) 0.07 (17)
Nontypable  0.05 (11) 0.03 (7) 0.03 (7) 0.03 (7)
Capsulated other than b 0 (0) 0 (0) 0.02 (4) 0.01 (3)
aIncludes isolates that were not serotyped.












Copy no. of 
cap e locus




Died Blood IV 1a 1
2 05/2000 35 M Meningitis Head trauma from 
car accident
Survived CSF IV 2 1
3 10/2000 65 M Septicemia Retro-peritoneal 
sarcoma
Died Blood IV 1 1
4 02/2001 98 F Bacteremic 
pneumonia
Chronic heart disease Died Blood IV 1 1
5 12/2001 33 F Meningitis None Survived CSF I 1 1
aHie, Haemophilus influenzae type e; CSF, cerebrospinal fluid; PFGE, pulsed-field gel electrophoresis; M, male; F, female.DISPATCHES
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(Table 2). All Hie isolates were unrelated to invasive Hib
strains circulating in Italy (9) (Figure). According to epidemi-
ologic data, patients with strains that showed an indistinguish-
able PFGE pattern did not appear to share any common risk
factor. Southern hybridization with the probe for the cap e
gene after PFGE identified a single fragment of 20.5 kb in
each isolate tested, suggesting the presence of one copy of the
cap locus (Table 2). 
Conclusions
Although studies on nasopharyngeal carriage of H. influen-
zae have shown the presence of serotype e as colonizer (11–
13), few studies have described serious infections attributable
to this capsular type (14–17). Our results suggest that Hie may
cause either fatal infections in elderly patients with underlying
disease or meningitis in adults whether or not underlying con-
ditions are present. In Italy, these cases of Hie infection are the
first reported. Despite limited data on the frequency of non–
type b invasive disease before 1997, our results are based on 4
years of laboratory-based active surveillance on a large popu-
lation sample. Since no type e strains were detected in the first
2 years of this surveillance, this clustering is likely due to the
emergence of invasive Hie disease. Alternative explanations
might include improved laboratory confirmation methods
(however, the proportion of meningitis cases without an identi-
fied etiologic agent did not decrease from 1998 to 2001) or
improved reporting in the last 2 years of surveillance (how-
ever, no changes to the system were made, and quality indica-
tors, such as proportion of isolates sent to the reference
laboratory, remained stable throughout the 4 years).
An unequivocal method of assigning capsular type is
required to monitor infection attributable to uncommon sero-
types, especially since, as in some Hie isolates, expression of
capsular polysaccharide is not sufficient to be detected by slide
agglutination (18). In our study, PCR capsular typing allowed
the identification of an additional Hie strain that had been mis-
identified by slide agglutination.
The prevalence of ampicillin resistance in both β -lacta-
mase–positive and –negative H. influenzae isolates has
increased worldwide. Neither β -lactamase production nor
intrinsic resistance was detected among our Hie isolates, con-
firming the low incidence of ampicillin-resistant H. influenzae
strains from invasive disease in Italy (5,9).
 PFGE has been successfully used to type H. influenzae
isolates. Our results suggest that two distinct Hie strains circu-
lated in Italy in 2000–2001. Four of the five isolates, found in
two neighboring regions, appeared to represent a unique clonal
group with two subtypes. This clustering of most strains in one
PFGE pattern might be explained with the clonal population
structure of encapsulated H. influenzae previously observed in
Italy (5,9), but further studies are needed to clarify this point.
Moreover, since the type e isolates analyzed in this study had
no close genetic relationship to the invasive Hib strain circu-
lating in Italy, their derivation from type b isolates by capsular
switch is unlikely. H. influenzae PFGE typing has a stronger
discriminatory power than biotyping (19). In our study, how-
ever, in the isolates assigned to the same clonal group by
PFGE, one was classified as biotype I, and the others were bio-
type IV. These findings suggest that biotyping could be a use-
ful adjunct to PFGE when typing Hie isolates. 
In our study, all five Hie isolates contained a single copy of
the cap locus, suggesting that they did not possess unusual vir-
ulent traits related to the capsule. Since the size of the restric-
tion fragment obtained was smaller than expected on the basis
of cap b locus size, a possible explanation may be that the size
of region 2 of cap e locus is smaller than that found in Hib
strains. Alternatively, the DNA flanking the cap e locus may
differ from that found in Hib strains; therefore, the segments
upstream and downstream from the cap e region would be
smaller.
Both the laboratory-based active surveillance of invasive
H. influenzae disease and PCR capsular genotyping could
have improved the capability to detect cases attributable to
serotypes other than b. Nevertheless, our data suggest the
Figure. Pulsed-field gel electrophoresis patterns of ApaI-digested chro-
mosomal DNAs of Haemophilus influenzae isolates. Lanes 1–5, H.
influenzae type e (Hie) isolates, respectively, from patient nos. 1–5;
lane 6, H. influenzae type b (Hib) strain belonging to one of the sub-
clones endemic in Italy (9); M, λ  ladder pulsed-field gel marker with
molecular weights indicated in kilobases (kb) at the right. The isolates
in lanes 3, 4, and 5 showed indistinguishable profiles (pattern 1); the
isolate in lane 1 was closely related to pattern 1 (pattern 1a), whereas
the isolate in lane 2 was clearly different from pattern 1 (pattern 2). All
Hie isolates were unrelated to the Hib strain.Emerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 261
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emergence of invasive Hie disease among the adult population
in Italy and underline the need to closely monitor infection
caused by non–type b strains. 
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